



Guidelines for abstract submission poster presenters

1. GUIDELINES

Abstracts can be submitted via the online abstract submission system on the congress website. We will accept standard/traditional abstracts on this platform. If you want to submit a clinical case, literature review or research proposal, please use the separate submission system for non-standard abstracts.

Abstracts should be prepared strictly according to the following instructions. Changes can not be made after the abstract submission deadline.

Content

- Abstracts should include:
 - brief introduction to the research question
 - aim(s) of the study
 - methods used including statistical analysis methods
 - summary of results containing real data and the outcome of statistical analyses
 - conclusions
- Abstracts must report on high quality research in the field of neuropsychopharmacology and/or (applied) neuroscience that has not been published whole elsewhere.
- The statements, particularly in the conclusion section, should be balanced.
- No abbreviations or trade names are allowed in the title. However, the generic name may be used.
- Use standard abbreviations for well-established neuropsychopharmaceuticals. Place unusual abbreviations in parentheses after the full word the first time it appears. Clearly identify all neuropsychopharmaceuticals used.
- Please indicate the topics of your abstract in ranking order making the first topic the most relevant.
- A disclosure on potential conflicts of interest (acknowledgement of funding) is requested when submitting an abstract.

Layout

- Abstracts must be submitted in English (UK).
- We encourage you to use the Neuroscience-based Nomenclature in the abstract. <http://www.nbn2.org/>
- The title should not exceed 20 words.
- Write the title in lower case letters (except the first letter) and do not put a dot at the end.
- Abstracts should have a minimum of 450 and a maximum of 500 words (excluding references).
- The use of underlined is not permitted. Words that need emphasis should be **bold** or *italics* type.
- Only one table is allowed, please note that graphs and pictures cannot be included. Tables cannot be inserted with copy/paste. Please create your table with the help of the 'table button' (top left, middle button).

References (optional)

- Optionally, you can include up to five references to previous publications. In the body text, a publication should be referred to by a consecutive number between brackets, i.e. [1], [2], [3], [4] and [5]. References indicated in the reference list, that are not linked to the body text will be deleted by the publisher.
- Authors are responsible for the accuracy of references. Only published articles and those in press (the journal should be stated) may be included; unpublished results and personal communications should be cited as such in the body text.
- It is the author's responsibility that the references are provided in accordance with *ENP journal referencing guidelines*. We recommend you to use the citation machine. The guidelines are available on our congress webpage.



Examples of references

Reference to a journal publication

[1] Chamberlain, S.R., Hampshire, A., Muller, U., Rubia, K., Del Campo, N., 2009. Atomoxetine modulates right inferior frontal activation during inhibitory control. A pharmacological functional magnetic resonance imaging study. *Biol. Psychiatry* 65(4), 550-555.

Reference to the DSM-5

[1] American Psychiatric Association, 2013. Diagnostic and statistical manual of mental disorders, fifth ed. American Psychiatric Association Publishing, Washington.

Reference to a book

[1] Strunk Jr., W., White, E.B., 1979. *The Elements of Style*, third ed. Macmillan, New York.

Reference to a chapter in a book

[1] Williams, K., 1980. Pharmacological dilemmas in psychiatry, in: Weaver, R., Smith, L.K., *Perspective on psychiatry*, second ed. Theme Press, Cornwall, 301-315.

Reference to a website

[1] McArthur, J., 2014. The link between schizophrenia and dementia, a new perspective. Available from: www.biopsychiatry.com/schizophrenia-dementia. [Accessed: 12 May 2015].

Reference to a DOI

[1] De Jong, A., 2015. Developments in the field of neuropsychopharmacology. *Pharm. Journal*, this issue, <http://dx.doi.org/10.2215.j.pharmjournal.2014.09.003>.

For more example please have a look at the model abstracts file.

Authors

- Insert the author's initials, last name and institute details as indicated on the on-line form. Do not add any titles or degrees: Prof, Dr, etc.
- The person submitting the abstract should be the author presenting the poster (presenting author). All communication will be done with the presenting author.

2. EVALUATION AND PUBLICATION

An abstract is eligible for review when:

- The abstract is submitted according to the guidelines on or before the deadline.
- The presenting author has registered and paid the congress registration fee within 2 weeks after submitting the abstract, and no later than 15 April 2020.

The abstracts submitted will be reviewed for:

- Presentation at the congress by means of a poster and/or e-poster.
- Publication in the congress supplement to the journal *European Neuropsychopharmacology*

All submitted abstracts (from registered presenting authors) will be evaluated by a scientific review committee. Authors will be informed of the committee's decision by e-mail before 1 July 2020. ECNP will not enter into discussion about the outcome.

The publisher of *European Neuropsychopharmacology* holds all publication rights including copyright.